Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry study of Qianggan Capsule for nonalcoholic fatty liver disease
ChiCTR2200058019Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of qianggan in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: ALT normalization or ≥30% reduction, Change in triglyceride ratio and normalization rate and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
qianggan
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2200058019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058019.